- Trials with a EudraCT protocol (207)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (69)
207 result(s) found for: Upper respiratory tract.
Displaying page 1 of 11.
EudraCT Number: 2006-002980-17 | Sponsor Protocol Number: BV-2005/01 PRIMES | Start Date*: 2007-07-12 | |||||||||||
Sponsor Name:OM PHARMA | |||||||||||||
Full Title: Double-blind, placebo-controlled, randomised clinical study of Broncho-Vaxom® in children suffering from recurrent upper respiratory tract infections | |||||||||||||
Medical condition: Recurrent upper respiratory tract infections in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) CZ (Completed) AT (Completed) IT (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021422-35 | Sponsor Protocol Number: 09-NI-EP-001 | Start Date*: 2010-10-26 | |||||||||||
Sponsor Name:Deutsche Homöopathie-Union, DHU-Arzneimittel GmbH & Co. KG | |||||||||||||
Full Title: Efficacy, safety and tolerability of Influcid tablets in patients (1 to 65 years old) suffering from upper respiratory tract infections with flu-like symptoms. A randomized, international, multicen... | |||||||||||||
Medical condition: Diagnosed upper respiratory tract infection (URTI) with presence of the following symptoms for equal or less than for 24 hours : a)Fever (axillary temperature >= 37.5°C) and b)At least one upper ... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001760-31 | Sponsor Protocol Number: J0022XST302 | Start Date*: 2013-07-04 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence | |||||||||||||
Medical condition: Recurrent Upper-Respiratory Tract Infections (RURTI) | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) LT (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000973-24 | Sponsor Protocol Number: EK-NM-01-05 | Start Date*: 2005-06-14 | |||||||||||
Sponsor Name:ERREKAPPA EUROTERAPICI | |||||||||||||
Full Title: Nimesulide spray in the treatment of simpthomatic inflammation with pain of the oral cavity (faringitis, stomatitis, pharyngitis) pre e post dental extraction. Randomised controlled vs active drug... | |||||||||||||
Medical condition: DISEASES OF UPPER RESPIRATORY TRACT (GINGIVITIS; PHARYNGITIS; STOMATITIS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002705-19 | Sponsor Protocol Number: OMPeR | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO | |||||||||||||
Full Title: A phase IV, randomized, controlled, double-blind study on efficacy and safety of OM-85 in children with recurrent respiratory tract infections | |||||||||||||
Medical condition: Recurrent Respiratory Tract Infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001882-36 | Sponsor Protocol Number: ACHIEVE | Start Date*: 2020-05-07 | |||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||
Full Title: ANTI-INFLAMMATORY CLARITHROMYCIN TO IMPROVE SARS-CoV-2 (COVID-19) INFECTION EARLY: THE ACHIEVE OPEN-LABEL NON-RANDOMIZED CLINICAL TRIAL | |||||||||||||
Medical condition: Management of infection by SARS-CoV-2 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001325-31 | Sponsor Protocol Number: NL73551.091.20 | Start Date*: 2020-05-20 | |||||||||||||||||||||
Sponsor Name:Radboud University Medical Center | |||||||||||||||||||||||
Full Title: [68Ga]Ga-DOTA-(RGD)2 PET/CT imaging of activated endothelium in lung parenchyma of COVID-19 patients. | |||||||||||||||||||||||
Medical condition: Maximum 10 patients from the Infectious Diseases ward with proven COVID-19 infection and pulmonary abnormalities on contrast-enhanced CT undergo static PET scans after injection of 70 μg (200 MBq) ... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-000472-28 | Sponsor Protocol Number: MK-7264-013 | Start Date*: 2018-06-01 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 2a, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of MK-7264 on Acute Cough in Participants with Induced Viral Upper Respiratory Tract Infe... | |||||||||||||
Medical condition: Acute cough in participants with induced viral upper respiratory tract infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005187-25 | Sponsor Protocol Number: BUC-SI-11-001 | Start Date*: 2012-05-31 | |||||||||||
Sponsor Name:SOCIETA' LABORATORIO FARMACEUTICO S.I.T. SRL | |||||||||||||
Full Title: Efficacy and tolerability clinical trial of an immunostimulant made from inactivated bacteria (BUCCALIN) in the prophylaxis of infection of the airways (rhinotracheobronchitis, colds). Double-blind... | |||||||||||||
Medical condition: Episodes classified by upper respiratory infections (otitis, tonsillitis, sinusitis, pharyngotonsillitis, nasopharyngitis) and lower respiratory tract (bronchitis, pneumonia). | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000057-31 | Sponsor Protocol Number: ESTUAR001 | Start Date*: 2012-03-19 | ||||||||||||||||||||||||||
Sponsor Name:THERANOR sprl | ||||||||||||||||||||||||||||
Full Title: Multicentre, randomised, double-blind, parallel, placebo-controlled study evaluating the efficacy and safety of Early Self-Treatment of viral Upper respiratory tract infections with homeopathic ora... | ||||||||||||||||||||||||||||
Medical condition: Viral upper respiratory tract infections | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005576-32 | Sponsor Protocol Number: Argo01-05 | Start Date*: 2005-12-19 | |||||||||||
Sponsor Name:BRACCO | |||||||||||||
Full Title: TOLERABILITY OF A NEW FORMULATION OF ARGOTONE IN HEALTH VOLONTEERS | |||||||||||||
Medical condition: Rhinitis and nasal congestion | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011355-46 | Sponsor Protocol Number: IMP13700 | Start Date*: 2009-07-28 | |||||||||||
Sponsor Name:Bayer Consumer Care AG | |||||||||||||
Full Title: A double blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of acetylsalicylic acid combined with pseudoephedrine, compared with acetylsalicylic acid alone, and ps... | |||||||||||||
Medical condition: Nasal congestion and pain associated with viral upper respiratory tract infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001345-38 | Sponsor Protocol Number: UNIKINON-01/HOPE | Start Date*: 2020-04-02 | |||||||||||
Sponsor Name:Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. | |||||||||||||
Full Title: CHROLOQUINE PHOSPHATE AGAINST INFECTION BY THE NOVEL CORONAVIRUS SARS-CoV-2 (COVID-19): THE HOPE OPEN-LABEL, NON-RANDOMIZED CLINICAL TRIAL | |||||||||||||
Medical condition: Possible prevention of pneumonia from SARS-CoV-2 in patients staying home and improving symptoms of SARS-CoV-2 pneumonia in patients treated in hospital | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000979-24 | Sponsor Protocol Number: DSIT-2015-02 | Start Date*: 2016-07-06 |
Sponsor Name:Daiichi Sankyo Italia SpA | ||
Full Title: Randomized, prospective double-blind placebo controlled study for the evaluation of the number, duration and severity of Upper Respiratory Tract Infections in children with risk of recurrence after... | ||
Medical condition: upper respiratory tract infections in children at high risk of reccurence. | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-002474-36 | Sponsor Protocol Number: GS-US-218-0108 | Start Date*: 2014-11-24 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT... | |||||||||||||
Medical condition: Respiratory Syncytial Virus (RSV) Infection of the upper respiratory tract. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) GB (Completed) NL (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001958-10 | Sponsor Protocol Number: IMUNOR-201301 | Start Date*: 2013-09-04 | |||||||||||
Sponsor Name:ImunomedicA, a.s. | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Confirmatory Study Assessing Efficacy and Safety of the IMUNOR Therapy Versus Placebo in Children with Recurrent ... | |||||||||||||
Medical condition: Recurrent Respiratory Tract Infections | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-003855-32 | Sponsor Protocol Number: KI-PROLIFIC-2023 | Start Date*: 2023-03-30 | |||||||||||
Sponsor Name:Karolinska Institutet | |||||||||||||
Full Title: An Interventional, Double-Blinded, 2-Arm Study to Investigate the Efficacy of Orally Administered Nirmatrelvir/Ritonavir Compared With Placebo/Ritanovir in Non-hospitalized Adult Participants suffe... | |||||||||||||
Medical condition: Patients with Post-Acute COVID syndrome (PACS) in which extensive clinical and biochemical examinations have been performed. PACS patients experience a wide variety of symptoms related to physical... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-004363-34 | Sponsor Protocol Number: MB 0704/1707/03 | Start Date*: 2006-03-30 | |||||||||||
Sponsor Name:VALEAS | |||||||||||||
Full Title: Antibiotic therapy in children for the upper respiratory tract infections. Study of the ''tollerability profile'' of cefaclor and amoxicillin-clavulanate | |||||||||||||
Medical condition: Pharyngitis, Pharyngotonsillitis or Sinusitis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002475-29 | Sponsor Protocol Number: GS-US-218-1502 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hematopoietic Cell Transplant (HCT... | |||||||||||||
Medical condition: Respiratory Syncytial Virus (RSV) Infection of the lower respiratory tract. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000242-35 | Sponsor Protocol Number: 18CT0003 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:E-Pharma Trento SpA | |||||||||||||
Full Title: Randomized, double blind, double dummy, parallel-groups, clinical trial on efficacy and safety of ibuprofen/N-acetylcysteine fixed dose combination vs. individual components (ibuprofen and N-acetyl... | |||||||||||||
Medical condition: symptomatic non-complicated upper respiratory tract infections | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
